Pfenex, Inc. has entered into a research collaboration with bioengineering solutions provider, DNA2.0, to develop an optimized algorithm and process for the design and synthesis of genes to be expressed in Pseudomonas fluorescens, the microorganism used in the Pfenex Expression Technology platform.
 
“Pfenex Inc. is dedicated to the rapid and reliable production of high quality recombinant proteins for our partners,” said Dr. Bertrand Liang, chief executive officer of Pfenex. “Through this collaboration, two industry leaders will leverage their respective capabilities to advance the Pfenex Expression Technology platform.  We are very excited about this project with our long-standing gene synthesis partner, DNA2.0, because it allows us to enhance the capabilities of our technology which will enable us to increase the overall value proposition to our partners.”
 
“DNA2.0 is the industry leader in gene design and expression optimization,” said Jeremy Minshull, Ph.D., cofounder and chief executive officer of DNA2.0.” Our patented GeneGPS technology is based on experiment data from over-expressed synthetic genes, resulting in up to a 100-fold increase in protein expression.  We have successfully optimized expression for a variety of hosts, including bacteria, yeast, fungus, plant and mammalian, and we are excited to work with Pfenex to extend our expertise to the P. fluorescens system.”